# Timothy Wollaeger

> Timothy Wollaeger is a Series B investor at Sanderling Ventures backing Health Care. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures)
- Location: Greater San Diego Area, United States
- Total investments: 11
- Last investment: Jan 2024
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/timothy-wollaeger-b7b6408

Timothy Wollaeger is a Series B investor at Sanderling Ventures in Greater San Diego Area focused on Health Care and Information Technology. Tim has nearly thirty years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling as a Managing Director in 2002, as head of the firm's San Diego office.Mr. Wollaeger began his career at Baxter International where his last position was VicePresident and General Manager of the Company's operations in Mexico. In 1983 he joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer. Following Hybritech's acquisition by Eli Lilly & Co in 1986, he became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found and remained an active Board member in Pyxis, Vical and Biosite. All three of these companies became public and Pyxis was acquired by Cardinal Health in 1996 for a $1 billion.He then helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994, when he left to found the venture capital firm Kingsbury Capital Partners. Kingbury's investments include Aurora Biosciences, Amylin Pharmaceuticals, Phamis Software, Health Data Sciences, Senomyx, Sub-Q, TKT, Althea, and Digirad.In San Diego, he was named Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 27% |
| Information Technology | 3 | 27% |
| Medical | 1 | 9% |
| Hospital | 1 | 9% |
| Life Science | 1 | 9% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 18% |
| Series C | 2 | 18% |
| Funding Round | 2 | 18% |
| Series D | 1 | 9% |
| Post-IPO Equity | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M | Post-IPO Equity | Jan 22, 2024 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M | Series D | Mar 11, 2021 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M | Series C | May 22, 2020 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $4M | Series C | Jan 04, 2009 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $5.5M | Series B | Feb 13, 2008 |  |
| Asteres | Asteres Inc., founded in 2003, is a prescription and pharmacy automation technology group. They were the first company to commercialize a system to store and deliver finished prescriptions to consumers in retail pharmacy. ScriptCenter, which works like an ATM, allows consumers to pickup and pay for their prescriptions when the pharmacy is closed*or without waiting in line when the pharmacy is open. Retailers can extend prescription pickup hours without adding staff and also alleviate the stress of long lines at the pharmacy counter. Retailers particularly appreciate that ScriptCenter convenience brings consumers in the store and keeps them shopping unlike drive-thru or home delivery. The Asteres management team has extensive experience in healthcare automation in hospital & healthcare systems and retail pharmacy. The team is known for successfully growing technology companies that have intense focus on customer value and customer service. | $4M | Series C | Nov 01, 2007 |  |
| Alteer | Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging. | $9.4M |  | Oct 11, 2002 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $12M | Series C |  |  |
| Alteer | Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging. | $16.5M |  |  |  |
| Asteres | Asteres Inc., founded in 2003, is a prescription and pharmacy automation technology group. They were the first company to commercialize a system to store and deliver finished prescriptions to consumers in retail pharmacy. ScriptCenter, which works like an ATM, allows consumers to pickup and pay for their prescriptions when the pharmacy is closed*or without waiting in line when the pharmacy is open. Retailers can extend prescription pickup hours without adding staff and also alleviate the stress of long lines at the pharmacy counter. Retailers particularly appreciate that ScriptCenter convenience brings consumers in the store and keeps them shopping unlike drive-thru or home delivery. The Asteres management team has extensive experience in healthcare automation in hospital & healthcare systems and retail pharmacy. The team is known for successfully growing technology companies that have intense focus on customer value and customer service. |  | Series B |  |  |

10 of 11 investments shown.

## Co-investors
- [Bering Capital](https://shizune.co/investors/profile/bering-capital) — VC Fund, 2 deals together
- [Quark Venture](https://shizune.co/investors/profile/quark-venture) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together
- [Valence Life Sciences](https://shizune.co/investors/profile/valence-life-sciences) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Biogen](https://shizune.co/investors/profile/biogen-idec) — VC Fund, 1 deal together

## About Sanderling Ventures

VC Fund · San Mateo, United States

Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices,and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada.Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.

5 contacts available at Sanderling Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Fred Middleton | Managing Director | https://shizune.co/investors/profile/fred-middleton |
| Timothy C. Mills | Managing Director | https://shizune.co/investors/profile/timothy-c-mills |
| Timothy Wollaeger | Managing Director | https://shizune.co/investors/profile/timothy-wollaeger |
| Michael Dixon | Managing Director | https://shizune.co/investors/profile/michael-dixon-6 |
| Paulette Taylor | General Counsel & Principal | https://shizune.co/investors/profile/paulette-taylor |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Timothy Wollaeger invest in?

Timothy Wollaeger invests primarily in Health Care, Information Technology and Medical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Timothy Wollaeger last invest?

The most recent investment recorded for Timothy Wollaeger closed in Jan 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co